RxDoctor Payments DataLook up a doctor →

Zeid Kayali, MD

Internal Medicine · Colton, CANPI 1396777538

Payments from drug & device makers

$14,229,246in general payments, 2019–2025

Across 2,829 payments — averaging $5029.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$1.8M
  • Boehringer Ingelheim$1.8M
  • Mallinckrodt Hospital Products Inc.$1.5M
  • Eli Lilly$1.3M
  • Genentech, Inc.$1.1M
  • X4 Pharmaceuticals, Inc.$749K
  • plus $6M from 49 others
$10,443in research payments, 2019–2025

Across 8 payments — averaging $1305.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$6K
  • Pfizer$3K
  • Astellas Pharma Inc$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astrazeneca UK Limited11$1,826,684
Boehringer Ingelheim13$1,775,086
Mallinckrodt Hospital Products Inc.34$1,520,180
Eli Lilly47$1,262,315
Genentech, Inc.17$1,057,473
X4 Pharmaceuticals, Inc.124$748,810
Intercept Pharmaceuticals, Inc.137$666,486
Gilead206$638,732
Merck271$580,442
Novartis13$441,132
AbbVie(2 entities)329$399,830
Novo Nordisk AS854$341,557
GSK42$302,232
Exelixis Inc.62$285,144
Bristol Myers Squibb52$277,304
Sanofi US Services Inc.11$225,998
Provepharm Inc.2$220,761
Boehringer Ingelheim International GmbH121$209,848
E.r. Squibb & Sons, L.L.C.10$202,562
Takeda Pharmaceuticals U.S.A., Inc.57$197,781
Incyte Corporation7$154,437
Pfizer53$141,157
AstraZeneca6$135,779
Regeneron51$135,322
Bausch Health US, LLC47$106,971
Astellas Pharma Inc13$103,321
Shire North American Group Inc9$81,385
Madrigal Pharmaceuticals53$50,109
Roche TCRC, Inc.4$38,916
Bayer11$27,124
Intercept Pharma Europe Ltd.3$16,274
Amgen2$15,311
Boehringer Ingelheim RCV GmbH & Co KG3$14,815
Adare Pharmaceuticals, Inc.3$14,516
Agios Pharmaceuticals, Inc.1$8,500
La Jolla Pharmaceutical Company1$2,105
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC92$1,192
Sanofi14$391
Shionogi Inc6$354
Ipsen Biopharmaceuticals, Inc2$228
Eisai Inc.7$132
Albireo Pharma, Inc.5$95
Phathom Pharmaceuticals, Inc.2$63
Dova Pharmaceuticals3$62
Ardelyx, Inc.4$59
Regeneron Healthcare Solutions, Inc.2$56
Mirum Pharmaceuticals, Inc.2$37
Capsovision, Inc.2$35
Orphalan Inc1$29
Alnylam Pharmaceuticals Inc.1$26
Novo Nordisk1$24
Dynavax Technologies Corporation2$21
W. L. Gore & Associates, Inc.1$16
Redhill Biopharma Inc.1$13
Exact Sciences1$13

How this compares

$14,229,246 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California →

Medicare billing

Part B allowed, 2024
$92,122
Medicare patients
388
Services billed
773

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Colton

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →